Re: Da remiziramo...

by Sora 7/12/2020, 18:52

Dakle, da remiziram
Branitelji njih pol milijuna su jelte od srednje bogate države napravili jednu državu sirotinje
Da bi se mogli pohvaliti da imaju državu
I u kojoj je korona ustvari pizdin dim prema ostalim szrahotama
E šta bi tito reko da vidi šta ste mu napravili od hrvatske
Niš
Zakopao bi se sam

by Sora 7/12/2020, 18:58

Tre
Dabogda te korona srela
Šta mi se rugaš blentone
Situacija je stani pani a tebi gluposti na umu

by Guest 7/12/2020, 19:00

tre se nesh uzjebo.. :rasta

..s obzirom na njegov kapability,moze samo klince uciti kako sutati loptu...

by Guest 7/12/2020, 19:01

Legendovich wrote:Kayo ne zamaraj svoj mozgić ovim stvarima..gledaj samo boje...

by Guest 7/12/2020, 19:03

Sora wrote:Dakle, da remiziram
Branitelji njih pol milijuna su jelte od srednje bogate države napravili jednu državu sirotinje
Da bi se mogli pohvaliti da imaju državu
I u kojoj je korona ustvari pizdin dim prema ostalim szrahotama
E šta bi tito reko da vidi šta ste mu napravili od hrvatske
Niš
Zakopao bi se sam

da bi rijec reko ili dodo... :rasta

by T. 7/12/2020, 19:10

Legendovich wrote:
Legendovich wrote:Kayo ne zamaraj svoj mozgić ovim stvarima..gledaj samo boje...

Ovo samo ero i eventualno gnječ razumiju, ove vjeverice šta li su...
Može li se to sažeti šta predstavlja?

by Šandor Winnetou 7/12/2020, 19:12

Sora wrote:Dakle, da remiziram
Branitelji njih pol milijuna su jelte od srednje bogate države napravili jednu državu sirotinje
Da bi se mogli pohvaliti da imaju državu
I u kojoj je korona ustvari pizdin dim prema ostalim szrahotama
E šta bi tito reko da vidi šta ste mu napravili od hrvatske
Niš
Zakopao bi se sam

branitelji imaju jednog ministra koji ne odlučuje o ničemu i zato baba bolje začepi lajavu gubicu ili udri brigu na veselje, bolje nego da sereš po stanici a vlak još nije ni krenio.

by Šandor Winnetou 7/12/2020, 19:13

Sora wrote:Tre
Dabogda te korona srela
Šta mi se rugaš blentone
Situacija je stani pani a tebi gluposti na umu

za vas jugosifiličare je takva situacija od 91 na ovamo.

by Šandor Winnetou 7/12/2020, 19:14

Legendovich wrote:tre se nesh uzjebo.. ..s obzirom na njegov kapability,moze samo klince uciti kako sutati loptu...

i komunjare, i lopine, i lažove, i lažne učitelje, i lažne specijalce...ima tu za šutanje pregršt vas nabrojanih

by Šandor Winnetou 7/12/2020, 19:17

T. wrote:
Legendovich wrote:
Legendovich wrote:Kayo ne zamaraj svoj mozgić ovim stvarima..gledaj samo boje...

Ovo samo ero i eventualno gnječ razumiju, ove vjeverice šta li su...
Može li se to sažeti šta predstavlja?

to ti je svrtozarev mishung halirung koji liječi sve, od korone do mrtvačkih pjega.
Ako uskoro pročitaš da su u njemačkoj nekoga uvaljali u katran i perije znati ćeš da se radi o robiju!

by Guest 7/12/2020, 19:20

T. wrote:
Legendovich wrote:
Legendovich wrote:Kayo ne zamaraj svoj mozgić ovim stvarima..gledaj samo boje...

Ovo samo ero i eventualno gnječ razumiju, ove vjeverice šta li su...
Može li se to sažeti šta predstavlja?

Da,za njih i jeste...kune su uporabljene u testiranju medikamenta...ostalo cekaj Gnjecu..Ero se zajebava

by Guest 7/12/2020, 19:23

T. wrote:
Legendovich wrote:
Legendovich wrote:Kayo ne zamaraj svoj mozgić ovim stvarima..gledaj samo boje...

Ovo samo ero i eventualno gnječ razumiju, ove vjeverice šta li su...
Može li se to sažeti šta predstavlja?

to je novo istraživanje jednog antiviralnog lijeka naziva Molnupiravir

Oral antiviral drug Molnupiravir can block spread of SARS-CoV-2 virus in ferrets, study shows

Molnupiravir is now in the advanced phase, multi-centre, clinical II/III trials in human beings after successful completion of phase I safety trials.

For the first time since the COVID-19 pandemic began in December last year, an antiviral oral drug has been developed that can stop the spread of the transmission of SARS-CoV-2 within 24 hours. The study was conducted by a group of researchers from the Institute for Biomedical Sciences at Georgia State University and funded by public health grants from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases to Georgia State.

The results have been published in the journal Nature Microbiology.

MK-4482/EIDD-2801, better known as Molnupiravir, could be a game-changer in stopping community transmission of COVID-19 till the time a vaccine is approved and distributed among the masses. The study indicates that the antiviral could have a three-fold benefit, as per a statement from the University. Molnupiravir can stop the progress of a patient from mild to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of isolation while putting an end to local outbreaks.

https://www.firstpost.com/health/oral-antiviral-drug-molnupiravir-can-block-spread-of-sars-cov-2-virus-in-ferrets-study-shows-9088761.html

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

https://www.nature.com/articles/s41564-020-00835-2

by Guest 7/12/2020, 19:26

Etoc..Gnječo dosao... cheers

dobro stavim puni tekst...

ne..previse ima..evo linka

https://www.nature.com/articles/s41564-020-00835-2

by Guest 7/12/2020, 19:29

ima opcija daunlodanja teksta,pa tko hoce prouciti..

gnječo imas desno na stranici gore odlican link za skidanje pdf-a

by Guest 7/12/2020, 19:34

Legendovich wrote:Etoc..Gnječo dosao...

dobro stavim puni tekst...

ne..previse ima..evo linka

https://www.nature.com/articles/s41564-020-00835-2

pa ja sam već stavio link i sad ga ti opet stavljaš. isti link. mogao si link staviti odmah a ne samo tabelu.

by Guest 7/12/2020, 19:36

Legendovich wrote:ima opcija daunlodanja teksta,pa tko hoce prouciti..

gnječo imas desno na stranici gore odlican link za skidanje pdf-a

hvala. da nije tebe živio bi u neznanju.

by Guest 7/12/2020, 19:38

Gnječ wrote:
Legendovich wrote:ima opcija daunlodanja teksta,pa tko hoce prouciti..

gnječo imas desno na stranici gore odlican link za skidanje pdf-a

hvala. da nije tebe živio bi u neznanju.

eto vidis..rado ja pomognem.. :rasta

by Guest 7/12/2020, 19:42

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active (can be taken orally) and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.[1][2] Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.[3]

The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.

Safety Controversy
In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic properties (producing birth defects).[4] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.[5]

COVID-19
After being found to be active against SARS-CoV-2 in March 2020, molnupiravir was tested in a preliminary human study for "Safety, Tolerability, and Pharmacokinetics" in healthy volunteers in the UK and US.[6] In June 2020, Ridgeback Biotherapeutics announced it was moving to Phase II trials to test the efficacy of the drug as a treatment for COVID-19.[7] Two trials of small numbers of hospitalized and non-hospitalized patients in the US and the UK were underway in July.[8][9] In late July 2020, and without yet releasing any medical data, Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move molnupiravir to late stage trials beginning in September 2020.[10] On October 19 2020, Merck began a one year Stage 2/3 trial focused on hospitalized patients.[11]

by Šandor Winnetou 7/12/2020, 19:45

Legendovich wrote:
Gnječ wrote:
Legendovich wrote:ima opcija daunlodanja teksta,pa tko hoce prouciti..

gnječo imas desno na stranici gore odlican link za skidanje pdf-a

hvala. da nije tebe živio bi u neznanju.
eto vidis..rado ja pomognem..

i tako propade još jedan pokušaj uvlačenja u stražnjicu našeg menagera,......... i po najnovijem lekara, apotekara, kemičara...da skratim trovača svetozara, korisnicima ovog foruma :)

by vuksadinare 7/12/2020, 19:57

Imam koronu...

by Šandor Winnetou 7/12/2020, 20:04

Samo se javljaj redovno i drž se

p.s. ne uzimaj mishung inhalirung ni za živu glavu

by Sponsored content